Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.,Clinical & Experimental Allergy

当前位置： X-MOL 学术 › Clin. Exp. Allergy › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype.
Clinical & Experimental Allergy ( IF 6.1 ) Pub Date : 2020-05-13 , DOI: 10.1111/cea.13613
Corrado Pelaia ₁ , Claudia Crimi ₂ , Girolamo Pelaia ₁ , Santi Nolasco ₂ , Raffaele Campisi ₂ , Enrico Heffler ₃ , Giuseppe Valenti ₄ , Nunzio Crimi ₂

Affiliation

Anti‐interleukin‐5 (IL‐5) monoclonal antibodies can be used as add‐on biological therapies in allergic and non‐allergic patients with severe eosinophilic asthma. However, within such a therapeutic context real‐life investigations are lacking.

中文翻译：